Market Overview

BioTime to Announce Second Quarter 2018 Results on August 2, 2018


BioTime, Inc. (NYSE:BTX), a clinical-stage biotechnology
company focused on degenerative diseases, today announced that it will
release second quarter 2018 financial and operating results on Thursday,
August 2, 2018, after the close of the U.S. financial markets. The
Company will host a conference call and webcast on Thursday, August 2,
2018, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss the
results and recent corporate developments.

The conference call dial-in number in the U.S./Canada is 1-866-888-8633.
For international participants outside the U.S./Canada, the dial-in
number is 1-636-812-6629. For all callers, please refer to Conference ID
number 1389978. The live webcast can be accessed on the "Events
& Presentations
" page of the "Investors & Media" section on the
company's website.

A replay of the conference call will be available for seven business
days beginning about two hours after the conclusion of the live call, by
calling toll-free from U.S./Canada: 1-855-859-2056; international
callers dial 1-404-537-3406. Use the Conference ID number 1389978.
Additionally, the archived webcast will be available on the "Events
& Presentations
" page of the "Investors & Media" section on the
company's website.

About BioTime, Inc.

BioTime is a clinical-stage biotechnology company focused on
degenerative diseases. Its clinical programs are based on two platform
technologies: cell replacement and cell/drug delivery. With its cell
replacement platform, BioTime is producing new cells and tissues with
its proprietary pluripotent cell technologies. These cells and tissues
are developed to replace those that are either rendered dysfunctional or
lost due to degenerative diseases or injuries. BioTime's cell/drug
delivery programs are based upon its proprietary HyStem® cell
and drug delivery matrix technology. HyStem® was
designed, in part, to provide for the transfer, retention and/or
engraftment of cellular replacement therapies. BioTime's lead cell
delivery clinical program is Renevia®, which consists of
HyStem® combined with the patient's own adipose (fat)
progenitor cells. Renevia® met its primary endpoint in an EU
pivotal clinical trial for the treatment of facial lipoatrophy in HIV
patients in 2017. BioTime has submitted Renevia® for
CE Mark approval in the EU. There were no device related serious adverse
events reported to date. BioTime's lead cell replacement product
candidate is OpRegen®, a retinal pigment epithelium
transplant therapy, which is in a Phase I/IIa multicenter clinical trial
for the treatment of dry age-related macular degeneration, the leading
cause of blindness in the developed world. There have been no unexpected
serious adverse events reported to date. BioTime also has significant
equity holdings in two publicly traded companies, Asterias
Biotherapeutics, Inc. (NYSE:AST) and OncoCyte
Corporation (NYSE:OCX), and a private company, AgeX
Therapeutics, Inc.

BioTime common stock is traded on the NYSE American and TASE under the
symbol BTX. For more information, please visit or
connect with the company on Twitter,
and Google+.

To receive ongoing BioTime corporate communications, please click on the
following link to join the Company's email alert list:

View Comments and Join the Discussion!